Regenerex Pharma (RGPX) Return on Capital Employed (2013 - 2025)

Regenerex Pharma (RGPX) has 11 years of Return on Capital Employed data on file, last reported at 64.58% in Q3 2025.

• Return on Capital Employed for Q3 2025 came in at 64.58%, up 3982.0% year-over-year; the trailing twelve-month figure through Sep 2025 was 64.58% (up 3982.0% YoY), and the FY2025 annual result was 46.72%, down 5354.0% from the prior year.
• Return on Capital Employed advanced to 64.58% in Q3 2025 per RGPX's latest filing, from 57.45% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 127.72% in Q3 2023 and troughed at 7.8% in Q2 2021.
• A 5-year average of 48.71% and a median of 24.6% in 2024 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2023 and 2024: Return on Capital Employed surged 11056 bps in 2023, then tumbled 10296 bps in 2024.
• A 5-year view of Return on Capital Employed shows it stood at 18.56% in 2021, then slumped by 38 bps to 11.49% in 2022, then surged by 949 bps to 120.49% in 2023, then sank by 80 bps to 24.44% in 2024, then jumped by 164 bps to 64.58% in 2025.
• Business Quant data shows RGPX's Return on Capital Employed at 64.58% in Q3 2025, 57.45% in Q2 2025, and 46.01% in Q1 2025.